Research and Markets


Printer Friendly

Printed from http://www.researchandmarkets.com/reports/835717


Know the Other "Omics": Exploring Drug and Diagnostics Development Through Proteomics


Description: Genomics has paved the way for its cousin, proteomics, to secure its share of the “omics” hype. Researchers look to proteomics to deliver on the promise to assess the viability of drug targets for monitoring disease progression, optimizing disease management, and diagnosing diseases with more precision. While many challenges are inherent, given the complexities of protein-centric science, technological improvements in the field have resulted in important gains for biopharma.

Get the Answers You Need to Shape Your Strategy

- Partnering in proteomics is slowing despite the potential of the associated technologies to revolutionize drug discovery, diagnostics development, and disease management. What problems are inherent in protein biomarker research? What solutions have been developed to help overcome the obstacles?
- Navigating the proteomics research process of preparation, separation, identification, and validation is complex.
- Which step is most critical upstream to improve results downstream?
- Proteomics technologies give rise to a select set of protein biomarkers. What are the differences between biomarkers for drug discovery and those for diagnostics development?

Scope

- Proteomics technologies: 2DGE, MS, MALDI, SELDI, TOF, bioinformatics.
- Proteomics research process: Innovative methods of sample preparation, separation and capture, identifi cation and analysis, and clinical validation.
- Companies with valuable insight into protein biomarker discovery: 20/20GeneSystems, Caprion Proteomics, NextGen BioSciences, Oxford GlycoSciences.
- Outlook: Proteomics is approaching the long-awaited recognition that it has the potential to deserve. Novel tools now in use will improve greatly owing to collaborative initiatives that will stimulate innovation in protein research processes.


Contents: Executive Summary
- Strategic Considerations
- Stakeholder Implications

Introduction

Inherent Challenges in Researching Proteins

Proving the Value of Proteomics

Understanding the Proteomics Approach
- Sample Preparation
- Separation and Capture, Analysis and Identification
- Planning Ahead for Clinical Validation

Recent Perspectives on Proteomic Technologies
- Two-Dimensional Gel Electrophoresis
- Mass Spectrometry
- Bioinformatics Tools

Biopharma Players in the Protein Research Arena
- Caprion Proteomics
- NextGen Sciences
- Power3 Medical Products

Notable Initiatives in Proteomics
- Clinical Proteomic Technologies for Cancer
- Spectrum Expert Commentary

Revitalizing Personalized Medicine Through Proteomics
- Improvements in Proteomics
- Protein Assay Platforms
- Assay Availability
- At a Major Turning Point
- About the Author
- Human Plasma Proteome Project

Outlook
- Overcoming Key Challenges
- Building Capacity Through Collaboration

list of Tables

- Select Diagnostic Tests Based on Protein Biomarkers
- Advantages and Disadvantages of 2DGE and MS Technologies
- Select Protein Sequencing Databases
- Select Proteomics Companies of Interest
- Participants in the Clinical Proteomic Technologies for Cancer Initiative
- Pharmaceutical and Diagnostics Company Sponsors of the Human Plasma Proteome Project

List of Figures

- FDA Approval of NMEs Compared with R&D Spending, 2000-2008
- Sensitivities and Specific cities of Select FDA-Approved Protein Biomarkers
- Proteomics Research Process
- Comparison of Protein Sample Sources
- Number of Alliances Involving Proteomics, 2001-2008

Expert Commentary

Revitalizing Personalized Medicine Through Proteomics
M. Walid Qoronfleh, Ph.D., M.B.A.,
Vice President of Business Development at NextGen Sciences


Companies Mentioned - 20/20 GeneSystems - Abbott Labs - Accacia International - Agilent - Allele Biotechnology & Pharmaceuticals - Amersham (now GE Healthcare) - Argonne National Laboratory - AxCell Biosciences - Battelle Pacifi c Northwest Laboratories - BD Biosciences - Bio-Rad Laboratories - Biosite - BioVision - Bristol-Myers Squibb - Broad Institute of MIT and Harvard, Proteomic Platform and Cancer Program - Bruker Daltonics - Buck Institute for Age Research - California Pacifi c Medical Center - Caprion Proteomics - Ciphergen (now Bio-Rad Laboratories) - College of William and Mary - Dade Behring - DakoCytomation - Developmental Studies Hybridoma Bank at the University of Iowa - Discovery Park at Purdue University - Emory University - Epitome - European Bioinformatics Institute - Fred Hutchinson Cancer Research Center - Genomic Solutions - GenTel Biosciences - Harvard Institute of Proteomics - Harvard University and its affi liated hospitals (including Dana-Farber Cancer Institute and Massachusetts General Hospital) - Hoosier Oncology Group - Human Protein Atlas (KTH—Royal Institute of Technology; Stockholm, Sweden) - Hybrigenics - Indiana University - Indiana University—Purdue University Indianapolis - Indiana University School of Medicine - Institute for Systems Biology - Invitrogen - Johnson & Johnson - Large Scale Biology - Lawrence Berkeley National Laboratory - Massachusetts Institute of Technology - Matritech - Memorial Sloan-Kettering Cancer Center - Meso Scale Diagnostics - Michigan State University - Molecular Staging - Monarch Life Sciences - National Cancer Institute, Center for Cancer Research Tissue Array Program - National Cancer Institute, Frederick Advanced Technology Program - National Institute of Standards and Technology - New York University Medical Center - NextGen Sciences - Northeastern University - Novartis - Oxford GlycoSciences - Pfi zer - Plasma Proteome Institute - Predictive Physiology and Medicine - Procter & Gamble - Purdue University - Quadraspec - Roche Diagnostics - Rules-Based Medicine - Seattle Children’s Hospital and Regional Medical Center - Sequenom - Sigma-Aldrich - University of British Columbia - University of California, Los Angeles - University of California, San Francisco - University of Colorado at Boulder - University of Houston - University of Maryland, College Park - University of Michigan - University of Texas M.D. Anderson Cancer Center - University of Victoria Genome British Columbia Proteomics Centre - University of Virginia - University of Washington - Vanderbilt-Ingram Cancer Center - Vanderbilt University Medical Center - Zyomix


Ordering: Order Online - visit http://www.researchandmarkets.com/reports/835717

Order by Fax - using the order form below

Order By Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.


Research and Markets Page 1 of 2
Printed 27/11/2009 16:24:37
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to
646-607-1907 (from USA) or +353 1 6849977 (from Rest of World). If you have any questions please email help@researchandmarkets.net

Order information
Please verify that the product information is correct and select the format you require.
Product Name:
Know the Other "Omics": Exploring Drug and Diagnostics Development Through Proteomics
Web Address:
http://www.researchandmarkets.com/reports/835717
Office Code:
OC8HJNPOUMUXU

Report formats
Please enter the quantity of the report format you require.

Format Quantity Price
Electronic (PDF) - Single User €1,494.00



Contact information
Please enter all the information below in BLOCK CAPITALS.

First Name:   Last Name:  
Email Address:
Job Title:
Organisation:
Address:
City:
Postal/Zip Code:
Country:
Phone Number:
Fax Number:


Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)
Research and Markets Page 2 of 2
Printed 27/11/2009 16:24:37

Payment information

Please indicate the payment method you would like to use by selecting the appropriate box.

 Pay by Credit Card:
American Express
Diners Club
Master Card
Visa
Cardholder's Name:
Cardholder's Signature:
Expiry Date: /
Card Number:
CVV Security Code:
Issue Date: /   (Diners Club only)


 Pay by Check:
Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.


 Pay by Wire Transfer:
Please transfer funds to:

Account number: 83313083
Sort code: 98-53-30
Swift code: ULSBIE2D
IBAN number: IE78ULSB98533083313083
Bank Address: Ulster Bank,
27-35 Main St,
Blackrock,
Co. Dublin,
Ireland.
If you have a Marketing Code please enter it below:
Marketing Code:


Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)